Moderna mRNA flu vaccine to get FDA panel review
Summary
An FDA advisory panel will review Moderna’s experimental mRNA flu vaccine called MFLUSIVA on June 18. The panel will discuss the vaccine’s safety and effectiveness before making recommendations.Key Facts
- Moderna developed an mRNA flu vaccine called MFLUSIVA.
- The vaccine is still experimental, meaning it is not yet approved for general use.
- The FDA has scheduled an advisory panel meeting on June 18 to review this vaccine.
- The panel will assess the vaccine’s safety and effectiveness data.
- This review is part of the FDA’s process to decide if the vaccine should be approved.
- The decision comes after changes in FDA leadership aimed at stabilizing the agency’s review methods.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.